Imricor Medical Systems (ASX:IMR) Beneish M-Score: -3.33 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:IMR Imricor Medical Systems Inc ASX:IMR
43 GF Score
Price A$1.83
GF Value A$0.10
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Imricor Medical Systems Beneish M-Score?

Imricor Medical Systems ASX:IMR 43 Beneish M-Score is -3.33 as of Jul. 14, 2026. GuruFocus rates ASX:IMR with a GF Score™ of 43/100 and a GF Value™ of A$0.10 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 763 Medical Devices & Instruments companies, Imricor Medical Systems ranks better than 85.71% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.33 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Imricor Medical Systems's Beneish M-Score or its related term are showing as below:

ASX:IMR' s Beneish M-Score Range Over the Past 10 Years
Min: -4.17   Med: -2.92   Max: -1.73
Current: -3.33

During the past 8 years, the highest Beneish M-Score of Imricor Medical Systems was -1.73. The lowest was -4.17. And the median was -2.92.


Imricor Medical Systems Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Imricor Medical Systems's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imricor Medical Systems Beneish M-Score Chart

Imricor Medical Systems Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial -4.17 -2.51 -1.73 -2.09 -3.33

Imricor Medical Systems Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.73 0.00 -2.09 0.00 -3.33

ASX:IMR vs ABT, SYK, MDT: Beneish M-Score Comparison

For the Medical Devices subindustry, Imricor Medical Systems's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Imricor Medical Systems Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Imricor Medical Systems's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Imricor Medical Systems's Beneish M-Score falls into.


ASX:IMR
43GF Score
Imricor Medical Systems Inc ASX:IMR
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Imricor Medical Systems Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Imricor Medical Systems for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 2.2971+0.528 * 0.1382+0.404 * 0.4861+0.892 * 0.29+0.115 * 0.8235
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 4.3879+4.679 * -0.05614-0.327 * 0.6361
=-3.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was A$0.36 Mil.
Revenue was A$0.44 Mil.
Gross Profit was A$-3.06 Mil.
Total Current Assets was A$64.59 Mil.
Total Assets was A$68.86 Mil.
Property, Plant and Equipment(Net PPE) was A$3.23 Mil.
Depreciation, Depletion and Amortization(DDA) was A$1.20 Mil.
Selling, General, & Admin. Expense(SGA) was A$14.45 Mil.
Total Current Liabilities was A$26.14 Mil.
Long-Term Debt & Capital Lease Obligation was A$20.92 Mil.
Net Income was A$-38.11 Mil.
Gross Profit was A$-5.52 Mil.
Cash Flow from Operations was A$-28.72 Mil.
Total Receivables was A$0.55 Mil.
Revenue was A$1.51 Mil.
Gross Profit was A$-1.46 Mil.
Total Current Assets was A$28.97 Mil.
Total Assets was A$34.14 Mil.
Property, Plant and Equipment(Net PPE) was A$4.10 Mil.
Depreciation, Depletion and Amortization(DDA) was A$1.18 Mil.
Selling, General, & Admin. Expense(SGA) was A$11.36 Mil.
Total Current Liabilities was A$3.72 Mil.
Long-Term Debt & Capital Lease Obligation was A$32.97 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.363 / 0.439) / (0.545 / 1.514)
=0.826879 / 0.359974
=2.2971

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(-1.459 / 1.514) / (-3.061 / 0.439)
=-0.963672 / -6.972665
=0.1382

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (64.59 + 3.225) / 68.864) / (1 - (28.973 + 4.101) / 34.144)
=0.015233 / 0.031338
=0.4861

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.439 / 1.514
=0.29

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.181 / (1.181 + 4.101)) / (1.202 / (1.202 + 3.225))
=0.22359 / 0.271516
=0.8235

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(14.451 / 0.439) / (11.358 / 1.514)
=32.917995 / 7.501982
=4.3879

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((20.924 + 26.143) / 68.864) / ((32.968 + 3.72) / 34.144)
=0.683478 / 1.074508
=0.6361

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-38.105 - -5.522 - -28.717) / 68.864
=-0.05614

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Imricor Medical Systems has a M-score of -3.33 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -3.33 mean?
Imricor Medical Systems (ASX:IMR) has a Beneish M-Score of -3.33 as of Jul. 14, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Imricor Medical Systems and its competitors. According to the industry distribution chart, Imricor Medical Systems ranks #109 out of 763 companies in the Medical Devices & Instruments industry, placing it in the top 14.3%.
Is Imricor Medical Systems' Beneish M-Score too high?
Imricor Medical Systems' current Beneish M-Score is -3.33. Based on the distribution chart, Imricor Medical Systems ranks #109 out of 763 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Imricor Medical Systems has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Imricor Medical Systems' Beneish M-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Imricor Medical Systems ranks #109 out of 763 companies for Beneish M-Score. This places Imricor Medical Systems in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Imricor Medical Systems and its competitors. Imricor Medical Systems's current Beneish M-Score is -3.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imricor Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, Imricor Medical Systems (ASX:IMR) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.10, compared to a current price of A$1.83 — trading 1725% above its estimated fair value. The current Beneish M-Score is -3.33. Imricor Medical Systems' overall GF Score™ is 43/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Imricor Medical Systems (ASX:IMR), the current Beneish M-Score is -3.33 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Imricor Medical Systems (ASX:IMR) Overvalued in 2026?

Based on GuruFocus' analysis, Imricor Medical Systems stock appears to be overvalued. The current stock price of A$1.83 is trading 1725% above its estimated GF Value™ of A$0.10. GuruFocus considers Imricor Medical Systems to be Significantly Overvalued.

Key valuation signals for ASX:IMR:

  • Beneish M-Score: -3.33
  • GF Value™: A$0.10 vs. price of A$1.83 (1725% above fair value)
  • GF Score™: 43/100 with 10 warning signs

No single metric tells the full story. See the ASX:IMR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Imricor Medical Systems Business Description

Address 400 Gateway Boulevard, Burnsville, MN, USA, 55337
Imricor Medical Systems Inc is a medical device company that develops MRI-guided technology to address issues with traditional X-ray ablation procedures. Its principal business activities are designing, manufacturing, and selling MRI-compatible products for cardiac catheter ablation procedures to treat arrhythmias. The company's products include the Advantage-MR EP Recorder/Stimulator, Vision-MR Ablation Catheter, and Vision-MR Dispersive Electrode. Geographically, the company generates maximum revenue from Europe.
43GF Score

Get the complete analysis for ASX:IMR

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.83
Price
A$0.10
GF Value